Artikel von Marvin Herzberger
Marvin Herzberger is a publishing trader at TraderFox GmbH and group leader for the technical analysis of the DAX. He has been actively engaged in technical analysis since 2011. In this context, he has tested, analyzed, and evaluated various trading strategies in practical implementation. His area of expertise lies in swing trading. The analyses cover a short-term time horizon of up to 10 days.Latest from Marvin Herzberger
Sol-Gel Technologies: Topical Skin Cancer Inhibitor in Focus of Wall Street
Cantor Fitzgerald rates the stock as "Overweight" with a target of $200. The analyst points to an attractive...
GlobalFoundries: The long-term perspective convinces me. I opened a position today!
In modern AI data centers, not only the computing power of the chips is crucial, but also the speed at...
GlobalFoundries: 21 billion USD from Japan for new semiconductor plants in New York!
GFS takes over the operation of two plants in New York, supported by an investment of up to 21 billion...
GameStop: Strategy Shift, Insider Purchases of Nearly $100 Million, and a 52-Week High!
GameStop reduces unprofitable stores and focuses on efficient capital allocation. In September and...
Unity Software: Google Partnership Lowers Entry Barriers for Millions of Developers!
Unity Software (U) is experiencing high demand in the monetization sector, recently generating $0.546...
Centene: How a new "Gold Card" program aims to drive margins in the healthcare sector
Centene benefits from a strong market position in government health programs. Recently, the company...
Tower Semiconductor: Semtech Partnership Addresses the Energy Problem of AI Data Centers
Tower and Semtech contractually secure dedicated SiGe manufacturing capacities in three countries....
Bumble: Billion-Dollar Offer and Delisting as a Way Out of the Growth Dip?
Last night, Bumble (BMBL) (i.) caught my attention. Bumble differentiates itself in online dating by...
Electra Therapeutics: Is a price target of 32 USD paving the way for the first FDA approval for mHLH?
The business model focuses on SIRP immunotherapies for inflammatory and oncological diseases. Jefferies...
Moderna: Momentum Bull Rises to a Multi-Year High - The Outlined Trend Following Scenario has its Effect!
About Moderna (MRNA) , I last reported on this on September 17. Since then, the stock has risen from...
Biogen: Immunology serves as a new growth driver - JPMorgan upgrades assessment to Overweight and price target to 300 USD!
JPMorgan raises price target to 300 USD and rates with "Overweight". Data on Felzartamab and Litifilimab...
Bristol Myers Squibb: Phase 3 Data on Cancer Drug Validate the Expansion of Precision Oncology
The company focuses on acquisitions to offset revenue declines due to expiring patents. The active...
Nektar Therapeutics: 4.0 Billion USD Revenue Potential – Why a New Biologic Drives the Price Target to 130 USD
Leerink analyst assigns an "Outperform" rating with an ambitious price target of 130 USD for Nektar Therapeutics...
Fastly: AI Traffic Monetization Unleashes New Margin Potentials - Oppenheimer Upgrades Rating to Outperform!
Oppenheimer upgrades Fastly to "Outperform" with a price target of $35. The monetization of AI traffic...
TeraWulf: The Billion-Dollar Infrastructure Transformation for the AI Sector - Morgan Stanley Raises Price Target to $65!
The focus on high-performance computing (HPC) and AI infrastructure fundamentally expands the business...
Teva Pharmaceuticals: Schizophrenia Treatment Without Monitoring Requirements Gains U.S. Market Access
Teva is increasingly focusing on specialty medications and aims for up to $16.8 billion in revenue...
GoDaddy: Beyond the acquisition fantasy, the company has even more to offer with its realignment toward the "Agentic Open Web"!
At the end of September, GoDaddy (GDDY) (i.) came back into the spotlight for investors due to takeover...
Andritz: New Insights on Medium-Term Goals from Capital Markets Day!
The Andritz AG is becoming an essential substance stock for the energy transition. At the recent Capital...
Vir Biotechnology: FDA Fast Track Status and New Clinical Data as Potential Price Drivers - Barclays Sets Target at $30!
Vir Biotechnology (VIR) focuses on combating infectious diseases and cancer through the human immune...
GlobalFoundries: Agreement with TSMC to Establish US Manufacturing of Silicon Interposers for Advanced AI Packaging!
GFS will manufacture silicon interposers for AI chips in the USA for TSMC. The agreement alleviates...